Neurophysiological Effects of Daily Centrum Use on Mood and Well-Being: A Cognalyzer EEG Analysis in Adults Between 40-60

Official title

Mood and Well-Being Following 12 Weeks of Daily Centrum Silver Multivitamin Supplementation in Adults Between 40-60: A Neurophysiological EEG Study Using the Cognalyzer EEG Analysis

Overview

The goal of this clinical trial is to learn whether 12 weeks of use of Centrum® Silver Daily Multivitamin can improve mood, and overall well-being in older adults The main questions it aims to answer are: 1. Does daily use of the multivitamin over a 12 week period improve well-being indicators as measured using EEG-based and subjective mood tests? 2. Does perturbation in mood effects due to cognitive load after a battery of cognitive assessments improve after 12 weeks of multivitamin intake.

Detailed description

This was a prospective, single-arm, observational study evaluating the effects of regular use of a Centrum multivitamin on mood, measured with subjective questionnaires and neurophysiological responses in adults between 40-60.

Participants were recruited from a large group who participated in a 5 day nutritional intake monitoring program (ASA24®, https://epi.grants.cancer.gov/asa24/). The participants with the lowest scores on the ASA evaluation were selected to participate in the study. All participants provided written informed consent before any study procedures.

The study consisted of two visits: a baseline visit (EEG, questionnaires), a period of 12 weeks of daily multivitamin use, followed by a second visit assessing extended effects of product use. Daily monitoring and weekly questionnaires continued throughout the product intake period.

EEG recordings were analyzed using Cognalyzer® EEG-based metrics, including mood valence, relaxation, and mental arousal. The primary objective was to evaluate changes in neurophysiological and self-reported measures of stress and relaxation both before and after a battery of cognitive assessments; exploratory objectives included a variety of other well-being measures measured both using EEG and standardized psychometric tests.

Interventions

• Dietary supplement Centrum Silver Adult Multivitamin UPC 62107535670
  Dosage 1 pill per day for 12 weeks

Primary outcome measures

• Change in EEG-Derived Relaxation Level (REL) [Time frame: Comparison after 12 weeks of product use.]
• Change in EEG-Derived Mental Confusion Level (COL) [Time frame: Comparison after 12 weeks of product use.]

Secondary outcome measures (4)

• EEG-derived Arousal Effect Level (AEL) [Time frame: Comparison after 12 weeks of product use.]
• BRUMS Self-reported Mood Test [Time frame: Comparison after 12 weeks of product use.]
• EEG-derived Valence Effect Level (VEL), indicative of genreal positive or negative mood. [Time frame: Comparison after 12 weeks of product use.]
• EEG-derived Anxiety Effect Level (AXL) [Time frame: Comparison after 12 weeks of product use.]

Eligibility criteria

Inclusion criteria

• be between the ages of 40 to 60
• Answered affirmatively that they have consumed, or are interested in consuming the investigational product
• Willingness to comply with all study requirements, complete questionnaires, records, and assessments associated with the study and to complete the facility visit
• Has given voluntary, written, informed consent to participate in the study

Exclusion criteria

• does not currently consume a multivitamin or dietary supplement that includes more than two micronutrients
• Women who are pregnant or breastfeeding
• Any objections that preclude the application of the EEG headset
• Allergy or sensitivity to any products required for the EEG measurement (e.g. conductive gel)
• Subjects with forehead skin/scalp health issues. (eg dermatitis, head lice, etc)
• History of a clinically significant adverse event associated with the consumption of a multivitamin product or any of its stated ingredients
• History of dementia, schizophrenia or other psychotic disorder, inclusive of alcohol or drug abuse within the last 12 months, interest or participation in drug abuse treatment within the past 60 days, or familial history of psychosis
• History of any clinically significant brain injury, based on self-report
• The participant is currently experiencing a migraine
• Significant cardiovascular event in the past 6 months
• Major surgery in the past 3 months
• Self-reported HIV-, Hepatitis B- and/or C-positive diagnosis
• Impairment from any drug or alcohol during their study visit, as assessed by the Principal Investigator or Sub-Investigator
• Individuals who are unable to give informed consent
• Any other condition that, in the opinion of the Principal Investigator or Sub-Investigator, may adversely affect the participant's ability to complete the study or its measures, or poses significant risk to the participant.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model

Cohort

Study locations

Canada · 1 center

• Zentrela Inc Canadian Office — Hamilton

Publications

• McDonald AC, Gasperin Haaz I, Qi W, Crowley DC, Guthrie N, Evans M, Bosnyak D. Sensitivity, Specificity and Accuracy of a Novel EEG-Based Objective Test, the Cognalyzer(R), in Detecting Cannabis Psychoactive Effects. Adv Ther. 2021 May;38(5):2513-2531. doi: 10.1007/s12325-021-01718-6. Epub 2021 Apr 7. PMID 33826089

Identifiers

NCT: NCT07740135 · CUSIC-85

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗